Ma J et al. and Qi S et al. summarized 24 cases of Ph-positive de novo MDS in a case report with two literature reviews; however, only one case of μ-bcr could not continue imatinib treatment [4, 5]. The gene discussed is BCR; the disease is myelodysplastic syndrome.